Basilea Pharmaceutica Ag Stock Earnings Reports

Basilea reported a strong H1 2025 driven by continued Cresemba momentum, commercial progress with Zevtera and active pipeline advancement. Key financials: total revenue CHF 104 million (H1), operating profit CHF 24 million (H1), net cash position CHF 50.7 million (June 30, 2025). Cresemba in-market sales were USD 612 million (12 months to Mar 2025, ~25% YoY) resulting in higher royalty income; Cresemba and Zevtera related revenue for H1 was CHF 90.5 million. The company secured an additional USD 39 million BARDA tranche to support antifungal programs and initiated the second Phase III fosmanogepix study (molds) while FAST-IC (candida) is ongoing — both trials expected to read out in early 2028. Basilea in-licensed oral antibiotic ceftibuten-ledaborbactam (Phase III-ready) to address resistant cUTIs; Phase III expected to start in ~18 months with potential NDA around year-end 2028. Updated 2025 guidance: total revenue ~CHF 225 million, Cresemba/Zevtera revenue ~CHF 190 million, R&D ~CHF 105 million (increase mainly due to the in-license), and operating profit ~CHF 50 million. Strategic strengths include nondilutive funding, a partnering commercialization model (Zevtera U.S. launch with Innoviva), a diversified anti-infectives pipeline (commercial, Phase III and earlier-stage assets) and strong cash generation; near-term value drivers are Cresemba royalties, Zevtera U.S. launch and fosmanogepix Phase III progress. Risks include increased R&D spend, patent/exclusivity timelines (notably Cresemba exclusivity ending in some markets after 2027) and the execution risk of large Phase III programs.